CD36及其在肥胖中的作用
Nahuel Garcia1, Maiken Mellergaard2,3, Carlos Salomon4
1GECORP, Buenos Aires, Argentina.
概括
CD36在脂肪储存和子宫外脂肪积累中起着关键作用,有助于肥胖并发症. 了解CD36通路可能会导致针对脂质代谢的新型肥胖治疗方法.
科学领域:
- 代谢研究的研究.
- 肥胖研究的研究.
- 脂质代谢 脂质的代谢
背景情况:
- 肥胖是复杂的遗传和环境相互作用的结果.
- CD36是脂质代谢和子宫外脂肪沉积的核心.
- 在非脂肪组织中的子宫外脂肪积累驱动着与肥胖有关的疾病,如MASLD和心血管问题.
研究的目的:
- 审查CD36在脂质代谢和子宫外脂肪积累中的多方面的作用.
- 重新检查脂肪组织扩展性假设,将CD36作为关键调节剂.
- 探索CD36与肥胖倾向和管理的遗传联系.
主要方法:
- 文献综述侧重于CD36在脂质处理中的功能.
- 分析CD36在脂肪和非脂肪组织脂质储存中的作用.
- 检查将CD36与肥胖有关的遗传证据.
主要成果:
- CD36促进脂肪酸的吸收,并调节脂质的储存位置.
- CD36影响脂肪组织的扩展性,可能导致脂质溢出到异胎位.
- CD36通过细胞外囊泡参与组织间的沟通,放大了子宫外脂肪沉积.
- CD36中的遗传变异与肥胖易感性和管理相关.
结论:
- CD36是健康和病原性脂肪沉积之间的代谢临界点的关键调节者.
- 针对CD36通路提供了针对肥胖及其并发症的个性化治疗策略的潜力.
- 对CD36和细胞外囊泡相互作用的进一步研究可能会揭示新的治疗点.
关键词:
CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36宫外脂肪是什么意思 宫外脂肪肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖更多相关视频
06:08Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
2.8K
13:09Segmentation and Measurement of Fat Volumes in Murine Obesity Models Using X-ray Computed Tomography
Published on: April 4, 2012
16.5K
相关概念视频
01:24Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
161
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
161
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
225
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
225